Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of viral genome replication. [GOC:ai]
Viral genome replication is a tightly regulated process that is essential for the production of new viral particles. The process involves a series of steps, including: 1. **Entry**: The virus must first enter the host cell. This can occur through various mechanisms, such as direct fusion with the cell membrane, endocytosis, or receptor-mediated entry. 2. **Uncoating**: Once inside the host cell, the viral capsid must be removed to release the viral genome. This process is often triggered by changes in pH or by host cell enzymes. 3. **Replication**: The viral genome, which can be DNA or RNA depending on the virus, must be replicated. This process involves the synthesis of new viral nucleic acids using the host cell's machinery. For DNA viruses, replication occurs in the nucleus of the cell. For RNA viruses, replication can occur in the cytoplasm or in specialized compartments called viral factories. 4. **Transcription**: For some viruses, the viral genome must be transcribed into mRNA. This mRNA is then translated into viral proteins using the host cell's ribosomes. 5. **Translation**: The mRNA produced from the viral genome is then translated into viral proteins. These proteins are essential for the assembly of new viral particles. 6. **Assembly**: The newly synthesized viral proteins and nucleic acids assemble into new viral particles. This process often occurs in specific regions of the host cell, such as the cytoplasm or the nucleus. 7. **Release**: The newly assembled viral particles must be released from the host cell. This can occur through lysis of the cell, budding from the cell membrane, or other mechanisms. Viral genome replication is regulated at multiple levels, including: 1. **Transcriptional regulation**: The expression of viral genes is often regulated at the level of transcription. This can involve the binding of viral proteins to specific DNA sequences in the viral genome, or the interaction of viral proteins with host cell transcription factors. 2. **Post-transcriptional regulation**: Viral gene expression can also be regulated after transcription. This can involve the processing of viral mRNA, the stability of viral mRNA, or the translation of viral mRNA. 3. **Post-translational regulation**: Viral proteins can also be regulated after translation. This can involve the modification of viral proteins, the degradation of viral proteins, or the interaction of viral proteins with host cell proteins. The regulation of viral genome replication is critical for the success of viral infection. It ensures that the virus can replicate efficiently and produce a sufficient number of progeny viruses to spread to new host cells. The specific mechanisms of regulation vary depending on the virus, but they all share the common goal of optimizing the production of new viral particles.'
"
Protein | Definition | Taxonomy |
---|---|---|
Peptidyl-prolyl cis-trans isomerase A | A peptidyl-prolyl cis-trans isomerase A that is encoded in the genome of human. [PRO:DNx, UniProtKB:P62937] | Homo sapiens (human) |
Apoptosis regulator Bcl-2 | An apoptosis regulator Bcl-2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P10415] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
catechin | hydroxyflavan | ||
chlorcyclizine | chlorcyclizine: was heading 1964-94 (Prov 1964-73); CHLOROCYCLIZINE & HISTACHLORAZINE were see CHLORCYCLIZINE 1977-94; use PIPERAZINES to search CHLORCYCLIZINE 1966-94; histamine H1-blocker used both orally and topically in allergies and also for the prevention of motion sickness | diarylmethane | |
gossypol | Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer. | ||
alizarin | dihydroxyanthraquinone | chromophore; dye; plant metabolite | |
2,4-pyridinedicarboxylic acid | lutidinic acid : A pyridinedicarboxylic acid carrying carboxy groups at positions 2 and 4. | pyridinedicarboxylic acid | |
daminozide | daminozide: induces tumors | straight-chain fatty acid | |
paclitaxel | Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL). | taxane diterpenoid; tetracyclic diterpenoid | antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent |
epigallocatechin gallate | (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin. epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis) | flavans; gallate ester; polyphenol | antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite |
5,6,7,8-tetrahydro-1-naphthol | 5,6,7,8-tetrahydro-1-naphthol : 1-naphthol hydrogenated at C-5, -6, -7 and -8. | tetralins | |
epicatechin | (-)-epicatechin : A catechin with (2R,3R)-configuration. | catechin; polyphenol | antioxidant |
gallocatechol | (-)-epigallocatechin : A flavan-3,3',4',5,5',7-hexol having (2R,3R)-configuration. | catechin; flavan-3,3',4',5,5',7-hexol | antioxidant; food component; plant metabolite |
chelerythrine chloride | |||
prolinal | pyrrolidines | ||
epicatechin gallate | (-)-epicatechin-3-O-gallate : A gallate ester obtained by formal condensation of the carboxy group of gallic acid with the (3R)-hydroxy group of epicatechin. A natural product found in Parapiptadenia rigida. epicatechin gallate: a steroid 5alpha-reductase inhibitor; RN given refers to the (cis)-isomer; structure given in first source; isolated from green tea | catechin; gallate ester; polyphenol | EC 3.2.1.1 (alpha-amylase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; metabolite |
blastmycin | blastmycin: structure | amidobenzoic acid | |
apogossypol | apogossypol: structure in first source | ||
umi-77 | UMI-77: an Mcl-1 inhibitor; structure in first source | ||
4-(4-ethoxycarbonylanilino)-2-quinazolinecarboxylic acid ethyl ester | quinazolines | ||
thioguanine anhydrous | Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia. | 2-aminopurines | anticoronaviral agent; antimetabolite; antineoplastic agent |
oxalylglycine | N-oxalylglycine : An amino dicarboxylic acid that is iminodiacetic acid with an oxo substituent. It is used as an inhibitor of alpha-ketoglutarate dependent (EC 1.14.11.*) enzymes. oxalylglycine: structure given in first source | amino dicarboxylic acid; N-acylglycine | EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor |
cyclosporine | ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF | homodetic cyclic peptide | anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite |
sanglifehrin a | sanglifehrin A: binds cyclophilin A; isolated from Streptomyces; structure in first source | ||
ixabepilone | 1,3-thiazoles; beta-hydroxy ketone; epoxide; lactam; macrocycle | antineoplastic agent; microtubule-destabilising agent | |
(melle-4)cyclosporin | (melle-4)cyclosporin: a non-immunosuppressive analog of cyclosporin A | ||
cyclosporin g | cyclosporin G: similar immunosuppressive actions as cyclosporin, but without nephrotoxic side effects; cyclosporin A analog; MW 1217 | ||
scy-635 | |||
abt-737 | aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound | anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor | |
nutlin-3a | nutlin 3: an MDM2 antagonist; structure in first source | stilbenoid | |
N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide | benzamides | ||
MI-63 | MI-63 : An azaspiro compound resulting from the formal fusion of position 3 of 6-chloro-oxindole with position 3 of (2R,3SS5S)-3-(3-chloro-2-fluorophenyl)-5-(2,2-dimethylpropyl)-N-[2-(morpholin-4-yl)ethyl]pyrrolidine-2-carboxamide. It is a potent inhibitor of the MDM2-p53 interaction. | azaspiro compound; monochlorobenzenes; monofluorobenzenes; morpholines; oxindoles; pyrrolidines; secondary carboxamide | apoptosis inducer |
alisporivir | alisporivir: nonimmunosuppressive cyclosporin analog; structure/sequence in first source | homodetic cyclic peptide | anticoronaviral agent |
navitoclax | aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound | antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor | |
abt-199 | venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion. venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source. | aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine | antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor |
nvp-cgm097 | NVP-CGM097: an MDM2 and HDM2 inhibitor; structure in first source | ||
jy-1-106 | JY-1-106: a BH3 alpha-helix mimetic that functions as a pan-Bcl-2 inhibitor; structure in first source | ||
a-1155463 | A-1155463: a Bcl-X(L) inhibitor; structure in first source | ||
bm-1197 | BM-1197: inhibits both Bcl-xL and Bcl-2; has antineoplastic activity | ||
a-1331852 | A-1331852: a Bcl-X(L) inhibitor; structure in first source | ||
BDA-366 | BDA-366 : A member of the class of anthraquinone that is 1,4-diamino-9,10-anthraquinone in which the two amino groups are carrying 3-(diethylamino)-2-hydroxypropyl and (oxiran-2-yl)methyl substituents. It exhibits anti-cancer properties. BDA-366: has antineoplastic activity; binds Bcl-2 protein; structure in first source | anthraquinone; epoxide; secondary alcohol; secondary amino compound; tertiary amino compound | antineoplastic agent; apoptosis inducer |
apogossypolone | apogossypolone: has antineoplastic activity; structure in first source |